New Pharmacoeconomic Analysis Shows Lower Rate of Reintubation Observed With SURFAXIN® Treatment May Reduce Hospital Costs Associated with Bronchopulmonary Dysplasia

WARRINGTON, Pa., Dec. 4, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the release of data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with SURFAXIN®...